Life sciences, medical device and pharmaceutical organizations are continuing to adapt to the new pressures and complexities brought about by COVID-19. While some companies have experience dealing with government contracts and grants, many organizations are starting to navigate federal funding compliance requirements for the first time to support the elimination of the coronavirus. Life sciences organizations are also contemplating permanent disruptions to commercialization by searching for alternate methods to field-based promotion and education practices, product sampling, and healthcare organization (HCO) engagement.
Listen to our on-demand webinar to learn how life sciences organizations are navigating COVID-19 and adapting to the new normal. Our team of Value Architects™ discuss: